DR. MARK A MARINELLA MD NPI 1801888482

NPI Details

DR. Mark A Marinella, MD is a medical oncology internal medicine in Kettering, OH with 33 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Mark A Marinella, MD NPI is 1801888482. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: WRIGHT STATE UNIVERSITY BOONSHOFT SCHOOL OF MEDICINE
Graduation Year:1993

The provider's business location address is:

3120 GOVERNORS PLACE BLVD
KETTERING, OH
ZIP 45409-328
Phone: (937) 293-1622
Fax: (937) 245-6308

The NPI 1801888482 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Ct scan of chest with contrast (HCPCS:71260)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Ct scan of abdomen and pelvis before and after contrast (HCPCS:74178)
• Ct scan of chest without contrast (HCPCS:71250)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Transitional care management services for problem of high complexity (HCPCS:99496)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)

The enumeration date for this NPI number is 8/18/2005 and was last updated on 5/14/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.